|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
300.83 USD |
-2.33% | -1.22% | +27.84% | |
Published on 06/09/2025 at 06:58
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Alnylam Gets EU Approval for RNAi Drug to Treat Transthyretin Amyloidosis With Cardiomyopathy |
06:58am |
MT |
|
Transcode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board |
May. 28 |
CI |
|
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,124,217, According to a Recent SEC Filing |
May. 19 |
MT |
|
Alnylam Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 11:20 AM |
May. 14 |
|
|
Alnylam Pharmaceuticals, Inc. to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the Helios-B Phase 3 Study Results at Heart Failure 2025 Congress |
May. 12 |
CI |
|
Alnylam To Share Progress Across Its Transthyretin Amyloidosis Franchise Including Additional Analyses Of The Helios-B Phase 3 Study Results At Heart Failure 2025 Congress |
May. 12 |
RE |
|
UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating |
May. 02 |
MT |
|
Alnylam Q1 Non-GAAP Net Loss Narrows, Revenue Rises |
May. 01 |
MT |
|
Alnylam Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 01, 2025 |
May. 01 |
|
|
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 01 |
CI |
|
Earnings Flash (ALNY) Alnylam Pharmaceuticals Posts Q1 Revenue $594.2M, vs. FactSet Est of $588.4M |
May. 01 |
MT |
|
(ALNY) Alnylam Pharmaceuticals Sees Fiscal Year 2025 Revenue Range $2.05B – $2.25B |
May. 01 |
MT |
|
Earnings Flash (ALNY) Alnylam Pharmaceuticals Reports Q1 Loss $-0.01 Per Share, vs. FactSet Est of $-0.38 |
May. 01 |
MT |
|
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2025 |
May. 01 |
CI |
|
Alnylam’s Transthyretin Amyloidosis Drug Gets Positive Opinion From European Medicines Agency |
Apr. 28 |
MT |
|
Alnylam Receives Positive CHMP Opinion For Vutrisiran For The Treatment Of Attr Amyloidosis With Cardiomyopathy |
Apr. 28 |
RE |
|
Alnylam Pharmaceuticals, Inc. Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy |
Apr. 28 |
CI |
|
BofA Adjusts Price Target on Alnylam Pharmaceuticals to $328 From $325, Keeps Buy Rating |
Apr. 17 |
MT |
|
Alnylam Pharmaceuticals, Inc. Presents at 24th Annual Needham Virtual Healthcare Conference, Apr-08-2025 11:45 AM |
Apr. 08 |
|
|
Alnylam Pharmaceuticals’ Qfitlia Approved by FDA for Hemophilia A, B Treatment |
Mar. 31 |
MT |
|
Alnylam Pharmaceuticals, Inc. Presents New Data from the HeliOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy At the American College of Cardiology’s Annual Scientific Session 2025 |
Mar. 29 |
CI |
|
Fda Approves Alnylam Pharmaceuticals, Inc.’S Qfitlia? for the Treatment of Hemophilia A or B |
Mar. 28 |
CI |
|
Markets Rally on Tariff Rumors |
Mar. 24 |
 |
|
JPMorgan Upgrades Alnylam Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $328 From $280 |
Mar. 24 |
MT |
|
Analyst recommendations: General Mills, Ulta Beauty, Micron Technology, RH… |
Mar. 24 |
|
ALNY: Dynamic Chart
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.
More about the company
Buy
Last Close Price
300.83USD
Average target price
320.62USD
Spread / Average Target
+6.58%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
